NeurAxis Overview
- Status
-
Public
- Employees
-
22

- Stock Symbol
-
NRXS

- Share Price
-
$2.54
- (As of Friday Closing)
NeurAxis General Information
Description
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Contact Information
Website
www.neuraxis.comCorporate Office
- 829 South Adams Street
- Versailles, IN 47042
- United States
Corporate Office
- 829 South Adams Street
- Versailles, IN 47042
- United States
NeurAxis Stock Performance
As of 07-Feb-2025, NeurAxis’s stock price is $2.54. Its current market cap is $18.3M with 7.18M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.54 | $2.50 | $2.05 - $3.89 | $18.3M | 7.18M | 28.1K | -$0.40 |
NeurAxis Financials Summary
As of 30-Sep-2024, NeurAxis has a trailing 12-month revenue of $2.46M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 25,036 | 13,641 | ||
Revenue | 2,456 | 2,460 | 2,685 | 2,721 |
EBITDA | (8,022) | (9,228) | (4,325) | (2,954) |
Net Income | (8,386) | (14,627) | (4,780) | (3,028) |
Total Assets | 1,143 | 509 | 1,481 | 760 |
Total Debt | 477 | 224 | 599 | 439 |
NeurAxis Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
NeurAxis Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
NeurAxis Patents
NeurAxis Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220387817-A1 | Device and method for eradicating pathogens in nasal passages | Pending | 07-Jun-2021 | ||
US-20220370673-A1 | Disinfection chambers and tunnels | Pending | 15-Jun-2020 | ||
US-20220347474-A1 | External auditory canal therapy device | Pending | 26-Jun-2019 | ||
US-20220176151-A1 | External auditory canal photobiomodulation and audio therapy device | Pending | 26-Jun-2019 | ||
CA-3143304-A1 | External auditory canal photobiomodulation device | Pending | 26-Jun-2019 | A61N5/0603 |
NeurAxis Signals
NeurAxis Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
NeurAxis FAQs
-
Where is NeurAxis headquartered?
NeurAxis is headquartered in Versailles, IN.
-
What is the size of NeurAxis?
NeurAxis has 22 total employees.
-
What industry is NeurAxis in?
NeurAxis’s primary industry is Therapeutic Devices.
-
Is NeurAxis a private or public company?
NeurAxis is a Public company.
-
What is NeurAxis’s stock symbol?
The ticker symbol for NeurAxis is NRXS.
-
What is the current stock price of NeurAxis?
As of 07-Feb-2025 the stock price of NeurAxis is $2.54.
-
What is the current market cap of NeurAxis?
The current market capitalization of NeurAxis is $18.3M.
-
What is NeurAxis’s current revenue?
The trailing twelve month revenue for NeurAxis is $2.46M.
-
What is NeurAxis’s annual earnings per share (EPS)?
NeurAxis’s EPS for 12 months was -$0.40.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »